非酒精性脂肪性肝病患者肠道菌群及血清IL-17和INF-γ水平变化*

doi:10.3969/j.issn.1672-5069.2023.06.013

Abstract

Abstract: Objective The purpose of this study was to explore the changes of intestinal flora as well as serum interleukin-17 (IL-17) and interferon-gamma (INF-γ) levels in patients with nonalcoholic fatty liver diseases (NAFLD). Methods 102 patients with NAFLD, including simple fatty liver (SFL) in 64 cases and non-alcoholic steatohepatitis (NASH) in 38 cases, and 48 healthy individuals were encountered in our hospital between January 2019 and January 2022. The intestinal flora and serum IL-17 and INF-γ levels were determined and compared. Results The fecal lactobacilli, bifidobacteria numbers and the bifidobacteria/ enterococcus (B/E) ratio in patients with NAFLD were (8.9±0.3)lg CFU/g,(8.6±0.3)lg CFU/g and (0.9±0.2), all significantly lower than [(9.9±0.4)lg CFU/g, (9.7±0.4)lg CFU/g and (1.1±0.3), respectively, P<0.05], while the fecal enterococcus and enterobacter numbers were (8.2±0.3)lg CFU/g and (9.3±0.4)lg CFU/g, both significantly higher than [(7.4±0.2)lg CFU/g and (8.4±0.3)lg CFU/g, respectively, P<0.05] in healthy persons; serum INF-γ level was (172.6±28.7)ng/L, much lower than [(293.7±48.5)ng/L, P<0.05], while serum IL-17 level was (46.9±8.2)ng/L, much higher than [(13.0±2.4)ng/L, P<0.05] in healthy individuals; the fecal lactobacilli, bifidobacteria numbers and the B/E ratio in patients with NASH were (8.2±0.3)lg CFU/g,(7.9±0.3)lg CFU/g and (0.9±0.2), all significantly lower than [(9.3±0.4)lg CFU/g, (8.9±0.4)lg CFU/g and (1.1±0.3), respectively, P<0.05], while the fecal enterococcus and enterobacter numbers were(8.6±0.3)lg CFU/g and (9.5±0.4)lg CFU/g, both significantly higher than [(7.7±0.2)lg CFU/g and (8.4±0.3)lg CFU/g, respectively, P<0.05] in patients with SFL; serum IL-17 level was (55.4±9.7)ng/L, much higher than [(41.3±7.2)ng/L, P<0.05], while serum INF-γ level was (146.9±21.6)ng/L, much lower than [(212.6±36.4)ng/L, P<0.05] in patients with SFL. Conclusion The intestinal flora, and serum IL-17 and INF-γ levels change abnormally in patients with NAFLD, which might be related to the liver injury, and needs further investigation.

Key words: Nonalcoholic fatty liver diseases, Nonalcoholic steatohepatitis, Intestinal flora, Interleukin-17, Interferon-γ

Hou Yilin, Cao Fenghua, Ji Xiaoyan, et al. Changes of intestinal flora as well as serum interliukin-17 and interferon-γ levels in patients with nonalcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2023, 26(6): 819-822.

References

[1] Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology, 2020, 158(7):1851-1864.
[2] Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res, 2021, 52(1):25-37.
[3] Watanabe M, Tozzi R, Risi R, et al. Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: a comprehensive review of the literature. Obes Rev, 2020, 21(8):3024-3035.
[4] Wong WK, Chan WK. Nonalcoholic fatty liver disease: a global perspective. Clin Ther, 2021, 43(3):473-499.
[5] He S, Cui S, Song W, et al. Interleukin-17 weakens the NAFLD/NASH process by facilitating intestinal barrier restoration depending on the gut microbiota. mBio, 2022, 6(1):77-89.
[6] Li J, Chen Q, Yi J, et al. IFN-γ contributes to the hepatic inflammation in HFD-induced nonalcoholic steatohepatitis by STAT1β/TLR2 signaling pathway. Mol Immunol, 2021, 134(3):118-128.
[7] Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol, 2020, 115(7):1055-1065.
[8] Aron-Wisnewsky J, Warmbrunn MV, Nieuwdorp M, et al. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity. Gastroenterology, 2020, 158(7):1881-1898.
[9] 刘志平,赵致维,张金华.非酒精性脂肪性肝病患者肠道菌群与胰高血糖素样肽1的相关性分析.临床肝胆病杂志, 2020,36(1):136-139.
[10] 任士萌,梅璐,黄煌,等.非酒精性脂肪性肝病患者肠道菌群及生物化学指标相关性分析.中华肝脏病杂志,2019,27(5):369-375.
[11] 刘艳民, 曾静, 范建高. 2017亚太地区非酒精性脂肪性肝病指南简介.实用肝脏病杂志, 2017, 20(5):649-651.
[12] Juanola O, Martínez-López S, Francés R, et al. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health,2021,18(10):5227-5236.
[13] Fujii H, Kawada N, Japan Study Group of NAFLD Jsg-NAFLD. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci, 2020, 21(11):3863-3871.
[14] Arrese M, Arab JP, Barrera F, et al. Insights into nonalcoholic fatty-liver disease heterogeneity. Semin Liver Dis, 2021, 41(4):421-434.
[15] Behary J, Amorim N, Jiang XT, et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. Nat Commun, 2021, 12(1):187-196.
[16] Tilg H, Adolph TE, Dudek M, et al. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab, 2021, 3(12):1596-1607.
[17] Ding X, Jian T, Li J, et al. Chicoric acid ameliorates nonalcoholic fatty liver disease via the ampk/nrf2/nfκb signaling pathway and restores gut microbiota in high-fat-diet-fed mice. Oxid Med Cell Longev, 2020, 26(2):185-186.
[18] Sharpton SR, Schnabl B, Knight R, et al. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metab, 2021, 33(1):21-32.
[19] Hong Y, Sheng L, Zhong J, et al. Desulfovibrio vulgaris, a potent acetic acid-producing bacterium, attenuates nonalcoholic fatty liver disease in mice. Gut Microbes, 2021, 13(1):1-20.
[20] Mayneris-Perxachs J, Cardellini M, Hoyles L, et al. Iron status influences non-alcoholic fatty liver disease in obesity through the gut microbiome. Microbiome, 2021, 9(1):104-112.
[21] Ji Y, Yin Y, Sun L, et al. The molecular and mechanistic insights based on gut-liver axis: nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement. Int J Mol Sci, 2020, 21(9):3066-3074.
[22] Gong S, Feng Y, Zeng Y, et al. Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in mice. J Transl Med,2021,19(1):147-158.
[23] Ma S, Sun Y, Zheng X, et al. Gastrodin attenuates perfluorooctanoic acid-induced liver injury by regulating gut microbiota composition in mice. Bioengineered, 2021,12(2):11546-11556.

Changes of intestinal flora as well as serum interliukin-17 and interferon-γ levels in patients with nonalcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Han Shishan, Zhao Caiyan. Perspective of betatrophin in the development of nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(6): 930-933.
[2]	Gu Qi, Rui Fajuan, Ni Qianqian, et al. Chronic disease management in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(4): 457-459.
[3]	Fang Shanshan, Du Mingqiao, Wang Yue. Will the hypopituitarism lead to the occurrence of nonalcoholic fatty liver diseases? An preliminary study [J]. Journal of Practical Hepatology, 2023, 26(4): 504-507.
[4]	Qiu Liying, Wang Yingchun. Nonalcoholic fatty liver diseases and the intestinal microecology: Current state of the art, controversies, and perspectives [J]. Journal of Practical Hepatology, 2023, 26(3): 308-312.
[5]	Wang Lingyun, Zhou Yongjian. Gut microbiota in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 317-319.
[6]	Zhan Qirui, Duan Taimei, Yan Jie. Changes of serum amyloid A, plasma heme oxygenase-1 and bone morphogenetic protein 9 levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(3): 348-351.
[7]	Xu Haimiao, Zheng Ruiqi, Ding Huiguo. Short-term efficacy of pitavastatin and polyene phosphatidyl choline combination in the treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 352-355.
[8]	Su Peihua, Song Meifang, Zhao Caiyan. Is the incidence of hepatocellular carcinoma increased in patients with chronic hepatitis B and nonalcoholic fatty liver diseases? [J]. Journal of Practical Hepatology, 2023, 26(3): 445-448.
[9]	Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B? [J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.
[10]	Liu Gang, Zhang Hao, Hu Jun. Changes of serum miR-183-5p and miR-96-5p levels in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(2): 197-201.
[11]	Huang Danxia, Zhao Zhihui, Xiao Yuexing, et al. Berberine improves liver injuries and intestinal flora disorders in high-fat diet-induced non-alcoholic fatty liver disease in rats [J]. Journal of Practical Hepatology, 2023, 26(1): 23-26.
[12]	Chen Fenglian, Zhu Qinglan, Zhu Lingli, et al. Different activation of peripheral blood invariant natural killer T cells and CD4⁺/CD8⁺T cells in patients with nonalcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2023, 26(1): 31-34.
[13]	Li Xiangyang, Ding Guangwei, Jin Ming. Efficacy of entecavir in treatment of patients with chronic hepatitis B and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2022, 25(6): 776-779.
[14]	Wang Yumei, Yuan Xiangdong, Liu Yuling, et al.. Prevalence and clues for non-alcoholic steatohepatitis in obese children/adolescents [J]. Journal of Practical Hepatology, 2022, 25(6): 808-811.
[15]	Zhang Bin, Wang Yiyi, Shi Lei. Implications of peripheral blood mononuclear lymphocyte TXNIP/NLRP3 in patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2022, 25(6): 820-823.